Willem Verpoest, BelgiumJuly 15, 2020
Paolo VercelliniAugust 31, 2020
Carole Verhoeven, Netherlands
studied Chemistry at the Catholic University of Nijmegen (1989) and received her PhD on the metabolism of structurally related synthetic steroidal hormones in 2001 from the University of Groningen, The Netherlands. From 1994-2011 she was working for Organon/Schering-Plough/MSD in several positions in preclinical and clinical development. She was amongst others responsible for the global phase III clinical development of the combined oral contraceptive Zoely®.
In 2011, Carole joined the Clinical department of Unilever R&D where she was responsible for the strategic definition and delivery of the Foods Clinical Programs. Carole joined Pantarhei Oncology BV in 2015 as Chief Scientific Officer (CSO), responsible for the development strategy including clinical programs of estetrol for the treatment of breast and prostate cancer. Carole has published 24 scientific papers in peer-reviewed journals.